Fruquintinib is a highly selective inhibitor of vascular endothelial growth factor receptor (VEGFR) independently developed by Hutchison China MediTech Limited (Chi-Med), which inhibits the activity of VEGFR kinase, suppresses the phosphorylation of VEGFR2/3, leads to the proliferation of vascular endothelial cells and luminal formation, thereby inhibiting tumor angiogenesis and achieving anti-tumor proliferation effects. The gene discussed is KDR; the disease is neoplasm.